Clinical trial

Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy

NCT00424840

Study summary

ClinicalTrials.gov

Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Bortezomib 1.3 mg/m2 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Bortezomib 1.6 mg/m2 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Bortezomib 1.8 mg/m2 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Carboplatin AUC 6 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Bevacizumab Normalized identity: bevacizumab View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Taxotere Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2006-06-01

PhasePHASE1

Conditions

Lung Cancerverified · MONDO: lung cancer

Interventions

Bortezomib 1.3 mg/m2DRUG

Bortezomib 1.6 mg/m2DRUG

Bortezomib 1.8 mg/m2DRUG

Carboplatin AUC 6DRUG

BevacizumabDRUG · verified · RxNorm: bevacizumab

TaxotereDRUG

Sponsors & collaborators

University of Massachusetts, Worcesterlead sponsor

Millennium Pharmaceuticals, Inc.collaborator

Genentech, Inc.collaborator

Mapped research locations

WorcesterMassachusetts, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00424840 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.